The Hybrid Tomosynthesis trial is a groundbreaking study assessing the potential of a modified 3D screening technology to enhance the accuracy and outcomes of breast cancer detection. Building on the pilot study conducted in 2017-18, this new, larger trial at Maroondah BreastScreen, explores a hybrid 3D and 2D imaging approach that aims to improve cancer detection while maintaining efficient screen reading times to facilitate adoption.
BreastScreen trial of hybrid tomosynthesis vs. mammography screening
Outcome
The trial aims to provide implementation evidence of the effectiveness of hybrid tomosynthesis in screening, to inform the role of tomosynthesis screening in the BreastScreen Australia Program.
Publication
- Effectiveness of hybrid digital breast tomosynthesis/digital mammography compared to digital mammography in women presenting for routine screening at Maroondah BreastScreen: Study protocol for a co-designed, non-randomised prospective trial
- Effectiveness of hybrid digital breast tomosynthesis/digital mammography in women presenting for routine screening at Maroondah BreastScreen, Australia: Interim analysis - PubMed
Lead researchers
- Professor Nehmat Houssami
Professor of Public Health and NBCF Chair in Cancer Prevention, Daffodil Centre, The University of Sydney - Dr Darren Lockie
Clinical Director, Maroondah BreastScreen, Eastern Health
Partners
The University of Sydney
Eastern Health
Funding
The research is funded by the National Breast Cancer Foundation Endowed Chair Grant and the National Health and Medical Research Council Investigator (Leader) Grants awarded to Professor Nehmat Houssami.
